A5077085473- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Parkinson's Disease Mechanisms and Treatments
- Neuroscience and Neuropharmacology Research
- Genetic Neurodegenerative Diseases
- Glycogen Storage Diseases and Myoclonus
- Cancer Treatment and Pharmacology
- Cardiovascular Syncope and Autonomic Disorders
- Hereditary Neurological Disorders
- Neurological and metabolic disorders
- Pain Mechanisms and Treatments
- Voice and Speech Disorders
- Sleep and Wakefulness Research
- Epilepsy research and treatment
- Diet and metabolism studies
- Restless Legs Syndrome Research
- Mitochondrial Function and Pathology
- Ion channel regulation and function
- Autism Spectrum Disorder Research
- Neuroscience of respiration and sleep
- Sympathectomy and Hyperhidrosis Treatments
- Pharmacological Effects and Toxicity Studies
- Biochemical Analysis and Sensing Techniques
- Coffee research and impacts
- Ginkgo biloba and Cashew Applications
Parkinson's and Movement Disorder Institute
2015-2024
University of California, Riverside
2016-2024
Orange Coast Memorial Medical Center
2009-2024
University of Colorado Anschutz Medical Campus
2023
University of Colorado Denver
2023
Neurosciences Institute
2018-2023
British Columbia Institute of Technology
2021
University of California, San Francisco
2015
Long Beach Memorial Medical Center
2000-2013
Parkinson's UK
2013
Abstract Botulinum toxin type A (Dysport) has been shown in European studies to be a safe and effective treatment for cervical dystonia. This multicenter, double‐blind, randomized, controlled trial assessed the safety efficacy of Dysport dystonia patients United States. Eighty were randomly assigned receive one with (500 units) or placebo. Participants followed up 4 20 weeks, until they needed further treatment. They at baseline weeks 2, 4, 8, 12, 16, after was significantly more efficacious...
Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need.To evaluate the efficacy and safety ADS-5102 (amantadine) extended-release 274-mg capsules for LID patients with PD.A randomized, double-blind, placebo-controlled clinical trial was conducted between May 7, 2014, July 22, 2015, at 44 North American sites among PD treated levodopa who experienced least 1 hour troublesome per day mild functional impact.Patients were randomized to receive placebo...
Abstract ADS‐5102 is a long‐acting, extended‐release capsule formulation of amantadine HCl administered once daily at bedtime. This study investigated the safety, efficacy, and tolerability in Parkinson's disease (PD) patients with levodopa‐induced dyskinesia. was randomized, double‐blind, placebo‐controlled, parallel‐group 83 PD troublesome dyskinesia assigned to placebo or one three doses (260 mg, 340 420 mg) bedtime for 8 weeks. The primary efficacy analysis compared change from baseline...
ASPEN-1 was a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, duration of response, and safety 2 doses DaxibotulinumtoxinA for Injection (DAXI), novel botulinum toxin type A formulation in participants with cervical dystonia (CD).
Abstract Focal task‐specific dystonias are unusual disorders of motor control, often affecting individuals who perform complex repetitive movements. Musicians especially prone to develop these because their training regimens and intense practice schedules. Task‐specific dystonia occurring in keyboard or string instrumentalists usually affects the hand. In contrast, there have been few descriptions musicians with muscles face jaw. We report detailed clinical observations 26 professional brass...
Abstract The treatment of adductor spasmodic dysphonia using botulinum toxin A was conducted in 13 patients as a double‐blind, placebo‐controlled study. Patients were diagnosed independently by an interdisciplinary team consisting speech pathologists, otolaryngol‐ogist, and neurologist. or saline injected into each thyroarytenoid muscle under electro‐myographic laryngoscopic guidance. Botulinum markedly reduced perturbation, decreased fundamental frequency range, improved the spectrographic...
THAP1 encodes a transcription factor (THAP1) that harbors an atypical zinc finger domain and regulates cell proliferation. An exon 2 insertion/deletion frameshift mutation in is responsible for DYT6 dystonia Amish-Mennonites. Subsequent screening efforts familial, mainly early-onset, primary identified additional sequence variants non-Amish subjects.To examine large cohort of subjects with adult-onset THAP1.With high-resolution melting, all 3 exons were screened 1,114 dystonia, 96...
The vast majority of patients with primary dystonia are adults focal or segmental distribution involuntary movements. Although ∼10% probands have at least one first- second-degree relative to dystonia, large families suited for linkage analysis exceptional. After excluding mutations in known genes (TOR1A, THAP1 and CIZ1), whole-exome sequencing identified a GNAL missense mutation (c.682G>T, p.V228F) an African-American pedigree clinical phenotypes that include cervical, laryngeal...
Quantitative image analysis of high-resolution computed tomography (HRCT) performed at residual volume, before and after methacholine, is a sensitive method detecting small airways involvement in asthma response to therapy targeted the airways. Since an oral anti-leukotriene reaches via circulation, present authors hypothesised that treatment with montelukast would lead improved airway patency. A double-blind crossover study compared effect versus placebo for 4 weeks 16 mild-to-moderate...
IncobotulinumtoxinA (Xeomin®, NT 201) is a purified botulinum toxin type A free from accessory (complexing) proteins. Previous studies evaluated single sets of incobotulinumtoxinA injections for the treatment blepharospasm. Individualized injection intervals and other potential determinants efficacy safety need to be in prospective, longitudinal study. Subjects with blepharospasm who completed ≤20 weeks double-blind, placebo-controlled main period entered ≤69 open-label extension (OLEX)...